IP Library › Granted Patent US 10,246,508
Granted Patent B2
US 10,246,508 · App. 15/122,241 · Granted Apr 2, 2019

Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines

Inventor: Adi Mor (Tel Aviv, IL)
Assignee: CHEMOMAB LTD.
C07K16/24A61K2039/505A61K2039/545C07K2317/24C07K2317/31C07K2317/565C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,246,508
App. No.
15/122,241
Granted
Apr 2, 2019
Kind
B2
Abstract

Provided are isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2. The antibodies bind additional CCR3-binding chemokines. Further provided are methods for using of the antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.

Claims (3)

1. A nucleic acid molecule encoding a humanized antibody that binds to at least two CCR3-binding chemokines wherein said nucleic acid molecule comprises the sequence denoted by SEQ ID NO: 1 and SEQ ID NO: 2.

2. An expression vector comprising the nucleic acid molecule of claim 1 .

3. A host cell comprising the nucleic acid molecule of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2016
From: MOR, ADI
To: CHEMOMAB LTD.
Reel/Frame 039563/0670 →
Continuity (2)
Provisional Application 61947852 · Mar 4, 2014
Related Publication 20160368979A1 · Dec 22, 2016